PC
Polar Capital Portfolio holdings
AUM
$13.5B
1-Year Return
55.85%
This Quarter Return
+6.66%
1 Year Return
+55.85%
3 Year Return
+125.38%
5 Year Return
+259.12%
10 Year Return
–
AUM
$8.75B
AUM Growth
+$718M
(+8.9%)
Cap. Flow
+$358M
Cap. Flow
% of AUM
4.09%
Top 10 Holdings %
Top 10 Hldgs %
24.38%
Holding
284
New
46
Increased
107
Reduced
75
Closed
35
Top Buys
| 1 |
Microsoft
MSFT
|
$97.3M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
$65.6M |
| 3 |
Amazon
AMZN
|
$61.9M |
| 4 |
Nektar Therapeutics
NKTR
|
$60.8M |
| 5 |
Stryker
SYK
|
$57.2M |
Top Sells
| 1 |
PepsiCo
PEP
|
$77M |
| 2 |
Amgen
AMGN
|
$72.2M |
| 3 |
AET
Aetna Inc
AET
|
$69M |
| 4 |
Jazz Pharmaceuticals
JAZZ
|
$52.8M |
| 5 |
CELG
Celgene Corp
CELG
|
$50.3M |
Sector Composition
| 1 | Financials | 23.81% |
| 2 | Healthcare | 22.43% |
| 3 | Technology | 21.12% |
| 4 | Communication Services | 11.68% |
| 5 | Industrials | 7.47% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
226
Sarepta Therapeutics
SRPT
$1.96B
| $1.39M | 0.01% |
+25,000
| New | +$1.39M |
|
227
HUTCHMED
HCM
$2.74B
| $1.15M | 0.01% |
+30,000
| New | +$1.15M |
|
|
VRNA
228
Verona Pharma
VRNA
$9.2B
| $1.13M | 0.01% |
95,149
+19,232
| +25% | +$229K |
|
229
Summit Therapeutics
SMMT
$19.3B
| $1.11M | 0.01% |
100,000
| – | – |
|
|
RARX
230
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
| $1.06M | 0.01% |
125,000
-50,000
| -29% | -$425K |
|
231
Protagonist Therapeutics
PTGX
$3.77B
| $1.04M | 0.01% |
50,000
-100,000
| -67% | -$2.08M |
|
232
Enterprise Financial Services Corp
EFSC
$2.24B
| $824K | 0.01% |
+18,243
| New | +$824K |
|
|
DESP
233
DELISTED
Despegar.com
DESP
| $605K | 0.01% |
+22,000
| New | +$605K |
|
234
MongoDB
MDB
$26.4B
| $594K | 0.01% |
+20,000
| New | +$594K |
|
|
QD
235
Qudian
QD
$733M
| $324K | ﹤0.01% |
+25,846
| New | +$324K |
|
236
Workday
WDAY
$61.7B
| – | – |
-73,508
| Closed | -$7.75M |
|
237
Aecom
ACM
$16.8B
| – | – |
-71,655
| Closed | -$2.64M |
|
|
ADAP
238
Adaptimmune Therapeutics
ADAP
$10.9M
| – | – |
-100,000
| Closed | -$819K |
|
239
AGCO
AGCO
$8.28B
| – | – |
-371,657
| Closed | -$27.4M |
|
|
240
Amgen
AMGN
$153B
| – | – |
-387,500
| Closed | -$72.2M |
|
241
argenx
ARGX
$45.9B
| – | – |
-50,000
| Closed | -$1.12M |
|
|
AXDX
242
DELISTED
Accelerate Diagnostics
AXDX
| – | – |
-103,767
| Closed | -$23.3M |
|
243
Curis
CRIS
$21M
| – | – |
-25,876
| Closed | -$3.86M |
|
244
Criteo
CRTO
$1.22B
| – | – |
-336,314
| Closed | -$14M |
|
|
DFS
245
DELISTED
Discover Financial Services
DFS
| – | – |
-53,371
| Closed | -$3.44M |
|
246
Fidelity National Information Services
FIS
$35.9B
| – | – |
-297,270
| Closed | -$27.8M |
|
247
Liberty Media Series C
FWONK
$25.2B
| – | – |
-274,854
| Closed | -$10.1M |
|
248
HCA Healthcare
HCA
$98.5B
| – | – |
-194,000
| Closed | -$15.4M |
|
|
249
Jazz Pharmaceuticals
JAZZ
$7.86B
| – | – |
-361,018
| Closed | -$52.8M |
|
250
LivaNova
LIVN
$3.17B
| – | – |
-191,219
| Closed | -$13.4M |
|